Literature DB >> 8610798

Contrast sensitivity and other vision tests in the optic neuritis treatment trial.

J D Trobe1, R W Beck, P S Moke, P A Cleary.   

Abstract

PURPOSE: To determine the intercorrelation, prevalence of abnormality, and incremental detection value of vision tests in optic neuritis.
METHODS: We calculated the linear correlation of paired vision tests and prevalence of abnormal test values from baseline and six-month measurements of Snellen visual acuity, Pelli-Robson contrast sensitivity, Humphrey Field Analyzer mean deviation, and Farnsworth-Munsell 100-hue color vision in 438 patients entered in the Optic Neuritis Treatment Trial from 1988 to 1991. The incremental detection value of nonvisual acuity tests was defined as their frequency of abnormality when visual acuity was 20/20 or better.
RESULTS: All four vision-test results were highly intercorrelated at baseline and at six months. At baseline, contrast sensitivity had the highest prevalence of abnormality, but all vision tests were so often abnormal that differences were not clinically relevant. At six months, when visual recovery had occurred, contrast sensitivity was most often abnormal (2.2 X visual acuity; 1.8 X mean deviation; 1.5 X Farnsworth-Munsell 100-hue color vision test); when contrast sensitivity, mean deviation, or Farnsworth-Munsell 100-hue color vision was normal, visual acuity was 20/25 or better in 98% of patients.
CONCLUSIONS: The high intercorrelation of four vision tests suggests that optic neuritis affects a broad range of visual functions. Among non-visual acuity tests, Pelli-Robson contrast sensitivity proved to be a particularly practical and sensitive indicator of visual dysfunction in optic neuritis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610798     DOI: 10.1016/s0002-9394(14)75429-7

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  31 in total

1.  Bayesian adaptive estimation of the contrast sensitivity function: the quick CSF method.

Authors:  Luis Andres Lesmes; Zhong-Lin Lu; Jongsoo Baek; Thomas D Albright
Journal:  J Vis       Date:  2010-03-30       Impact factor: 2.240

Review 2.  Corticosteroids for treating optic neuritis.

Authors:  Robin L Gal; Satyanarayana S Vedula; Roy Beck
Journal:  Cochrane Database Syst Rev       Date:  2015-08-14

3.  Human vision with a lesion of the parvocellular pathway: an optic neuritis model for selective contrast sensitivity deficits with severe loss of midget ganglion cell function.

Authors:  Amal M Al-Hashmi; Daniel J Kramer; Kathy T Mullen
Journal:  Exp Brain Res       Date:  2011-10-18       Impact factor: 1.972

Review 4.  Clinical assessment of two new contrast sensitivity charts.

Authors:  Kavitha Thayaparan; Michael D Crossland; Gary S Rubin
Journal:  Br J Ophthalmol       Date:  2006-12-13       Impact factor: 4.638

Review 5.  Corticosteroids for treating optic neuritis.

Authors:  S S Vedula; S Brodney-Folse; R L Gal; R Beck
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

6.  Effect of higher order aberrations on contrast sensitivity function in myopic eyes.

Authors:  Sepehr Feizi; Farid Karimian
Journal:  Jpn J Ophthalmol       Date:  2009-09-08       Impact factor: 2.447

7.  [New aspects in the therapy of multiple sclerosis and optic neuritis].

Authors:  W Lagrèze; R Diem
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

8.  [Multiple sclerosis. An update with practical guidelines for ophthalmologists].

Authors:  T Ziemssen; H Wilhelm; F Ziemssen
Journal:  Ophthalmologe       Date:  2006-07       Impact factor: 1.059

9.  Anatomic and functional correlation of frequency-doubling technology perimetry (FDTP) in multiple sclerosis.

Authors:  Harold Merle; Stéphane Olindo; Angélique Donnio; Raymond Richer; Didier Smadja; Philippe Cabre
Journal:  Int Ophthalmol       Date:  2011-06-03       Impact factor: 2.031

10.  Disability in optic neuritis correlates with diffusion tensor-derived directional diffusivities.

Authors:  R T Naismith; J Xu; N T Tutlam; A Snyder; T Benzinger; J Shimony; J Shepherd; K Trinkaus; A H Cross; S-K Song
Journal:  Neurology       Date:  2008-12-10       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.